Benzinga | Oct 18, 2021 07:38AM EDT

BrainStorm Announces Scientific Presentation Of NurOwn Exosome Preclinical ARDS Data At NYSCF 2021 VIRTUAL Meeting

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF (NurOwn(r)) Exosomes in Acute Lung Injury Models" at the NYSCF 2021 VIRTUAL Meeting, being held on October 19-20, 2021. The poster will be presented tomorrow, October 19, at 3:45 -- 5:00pm Eastern Time.

POSTER HIGHLIGHTS:



* Lung diseases are one of the leading global causes of acute and chronic morbidity and mortality across all ages and are in need of innovative therapeutic solutions.



* Using two different acute lung injury models, lipopolysaccharide (LPS) and Bleomycin, we compared the effect of two types of small extracellular vesicles (sEVs): sEVs isolated from na?ve MSC (Exo MSC) or sEVs isolated from MSCs which were induced to secrete increased levels of regenerative and immunoregulatory factors (Exo MSC-NTF), based on the NurOwn technology platform.



* Results in both models showed that the beneficial effects of intratracheal administration of Exo MSC-NTF were superior to Exo MSC in multiple parameters, including increase in blood oxygen saturation and reduction in lung pathology, inflammatory infiltration and levels of proinflammatory cytokines in bronchoalveolar lavage fluid (BALF), in addition to reduction of lung fibrosis in Bleomycin model.



* Analysis of the respective protein cargo demonstrated higher levels of key regulatory molecules in MSC-NTF exosomes compared to MSC exosomes that may attenuate lung inflammation and promote lung repair, including leukemia inhibitory factor (LIF); amphiregulin (AREG); hepatocyte growth factor (HGF); and tumor necrosis factor-stimulated gene-6 (TSG-6).

The observed positive preclinical results suggest that intratracheal administration of Exo MSC-NTF may have clinical potential as a therapy for acute lung related pathologies and may be more effective at modifying physiological, pathological, and biochemical outcomes than sEVs isolated from na?ve MSCs.